Effect of Platelet Inhibition with Cangrelor during PCI on Ischemic Events
Identifikátory výsledku
Kód výsledku v IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11120%2F13%3A43907346" target="_blank" >RIV/00216208:11120/13:43907346 - isvavai.cz</a>
Nalezeny alternativní kódy
RIV/00064173:_____/13:#0000317 RIV/00064173:_____/13:N0000002
Výsledek na webu
<a href="http://dx.doi.org/10.1056/NEJMoa1300815" target="_blank" >http://dx.doi.org/10.1056/NEJMoa1300815</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1056/NEJMoa1300815" target="_blank" >10.1056/NEJMoa1300815</a>
Alternativní jazyky
Jazyk výsledku
angličtina
Název v původním jazyce
Effect of Platelet Inhibition with Cangrelor during PCI on Ischemic Events
Popis výsledku v původním jazyce
The intensity of antiplatelet therapy during percutaneous coronary intervention (PCI) is an important determinant of PCI-related ischemic complications. Cangrelor is a potent intravenous adenosine diphosphate (ADP)-receptor antagonist that acts rapidly and has quickly reversible effects. METHODS In a double-blind, placebo-controlled trial, we randomly assigned 11,145 patients who were undergoing either urgent or elective PCI and were receiving guideline-recommended therapy to receive a bolus and infusion of cangrelor or to receive a loading dose of 600 mg or 300 mg of clopidogrel. The primary efficacy end point was a composite of death, myocardial infarction, ischemia-driven revascularization, or stent thrombosis at 48 hours after randomization; the key secondary end point was stent thrombosis at 48 hours. The primary safety end point was severe bleeding at 48 hours. RESULTS The rate of the primary efficacy end point was 4.7% in the cangrelor group and 5.9% in the clopidogrel group (ad
Název v anglickém jazyce
Effect of Platelet Inhibition with Cangrelor during PCI on Ischemic Events
Popis výsledku anglicky
The intensity of antiplatelet therapy during percutaneous coronary intervention (PCI) is an important determinant of PCI-related ischemic complications. Cangrelor is a potent intravenous adenosine diphosphate (ADP)-receptor antagonist that acts rapidly and has quickly reversible effects. METHODS In a double-blind, placebo-controlled trial, we randomly assigned 11,145 patients who were undergoing either urgent or elective PCI and were receiving guideline-recommended therapy to receive a bolus and infusion of cangrelor or to receive a loading dose of 600 mg or 300 mg of clopidogrel. The primary efficacy end point was a composite of death, myocardial infarction, ischemia-driven revascularization, or stent thrombosis at 48 hours after randomization; the key secondary end point was stent thrombosis at 48 hours. The primary safety end point was severe bleeding at 48 hours. RESULTS The rate of the primary efficacy end point was 4.7% in the cangrelor group and 5.9% in the clopidogrel group (ad
Klasifikace
Druh
J<sub>x</sub> - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)
CEP obor
FA - Kardiovaskulární nemoci včetně kardiochirurgie
OECD FORD obor
—
Návaznosti výsledku
Projekt
—
Návaznosti
N - Vyzkumna aktivita podporovana z neverejnych zdroju
Ostatní
Rok uplatnění
2013
Kód důvěrnosti údajů
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Údaje specifické pro druh výsledku
Název periodika
New England Journal of Medicine
ISSN
0028-4793
e-ISSN
—
Svazek periodika
368
Číslo periodika v rámci svazku
14
Stát vydavatele periodika
US - Spojené státy americké
Počet stran výsledku
11
Strana od-do
1303-1313
Kód UT WoS článku
000316989900007
EID výsledku v databázi Scopus
—